Certificates related to Sanofi-Aventis's (SASY.PA) $20.1 billion acquisition of U.S. biotech firm Genzyme (GENZ.O) could begin trading on Nasdaq as soon as April 4, depending on the outcome of its tender offer. The French drugmaker said on Tuesday that the U.S. Securities and Exchange Commission (SEC) had cleared the trading of contingent value rights (CVR) under the ticker GCVRZ.O. Sanofi-Aventis clinched its long-sought deal to buy Genzyme in February with a sweetened offer that comprises cash and the possible payment under the CVRs of additional amounts geared to the future performance of several of the U.S. group's drugs. [ID:nLDE70U1H1]
Source
